Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Syros Goes For Reboot With New Investors And Leukemia Licensing

Bain Capital Leads $90.5m Investment

Executive Summary

Syros has failed to progress in its leukemia niche since its launch a few years ago, but a new drug candidate and funding could revive its fortunes.

You may also be interested in...



Syros Gets ‘Tyme’ To Bring Lead Candidate To Pivotal Readout

Gene-expression focused Syros adds about $190m to its coffers with Tyme merger and PIPE financing. This will get it past pivotal data for tamibarotene and enable Phase III development of a leukemia candidate.

Beam Therapeutics’ Base-Edited CAR-T Placed On Hold

Beam is the latest allogeneic CAR-T developer to face a regulatory hold-up, but other candidates using its pioneering base-editing technology are now progressing.

On A Roll, AstraZeneca Aims For ‘Industry-Leading’ Growth From 2025

AstraZeneca’s momentum is growing towards ‘industry-leading' revenue growth, but investors are focused on the operating margin, and concerned about when CEO Pascal Soriot will depart.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC143439

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel